|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Assessing liver injury associated with antimycotics:Concise literature review and clues from data mining of the FAERS database显示文摘AIM: To inform clinicians on the level of hepatotoxicrisk among antimycotics in the post-marketing setting,following the marketing suspension of oral ketocon-azole for drug-induced liver injury(DILI).METHODS: The publicly available international FAERSdatabase(2004-2011) was used to extract DILI cases(including acute liver failure events), where antimycot-ics with systemic use or potential systemic absorptionwere reported as suspect or interacting agents. The re-porting pattern was analyzed by calculating the report-ing odds ratio and corresponding 95%CI, a measure ofdisproportionality, with time-trend analysis where ap-propriate.RESULTS: From 1687284 reports submitted over the8-year period, 68115 regarded liver injury. Of these,2.9% are related to antimycotics(1964 cases, of which 112 of acute liver failure). Eleven systemic antimycotics(including ketoconazole and the newer triazole deriva-tives voriconazole and posaconazole) and terbinafine(used systemically to treat onychomicosis) generated a significant disproportionality, indicating a post-market-ing signal of risk.CONCLUSION: Virtually all antimycotics with systemic action or absorption are commonly reported in clinically significant cases of DILI. Clinicians must be aware of this aspect and monitor patients in case switch is con-sidered, especially in critical poly-treated patients under chronic treatment. | Emanuel Raschi Elisabetta Poluzzi Ariola Koci Paolo Caraceni Fabrizio De Ponti | 2014 | World Journal of Hepatology2014，6，8： | 10 |
| 2 | Drug-induced liver injury:Towards early prediction and risk stratification显示文摘Drug-induced liver injury(DILI) is a hot topic for clinicians, academia, drug companies and regulators, as shown by the steadily increasing number of publications and agents listed as causing liver damage(http://gffzz56cca2eee53b45d1hpc0kcpff9oqk6wnb.ffgz.tsg.suse.edu.cn/). As it was the case in the past decade with drug-induced QT prolongation/arrhythmia, there is an urgent unmet clinical need to develop tools for risk assessment and stratification in clinical practice and, in parallel, to improve prediction of pre-clinical models to support regulatory steps and facilitate early detection of liver-specific adverse drug events. Although drug discontinuation and therapy reconciliation still remain the mainstay in patient management to minimize occurrence of DILI, especially acute liver failure events, different multidisciplinary attempts have been proposed in 2016 to predict and assess drug-related risk in individual patients; these promising, albeit preliminary, results strongly support the need to pursue this innovative pathway. | Emanuel Raschi Fabrizio De Ponti | 2017 | World Journal of Hepatology2017，9，1： | 8 |
| 3 | Drug- and herb-induced liver injury:Progress,current challenges and emerging signals of post-marketing risk显示文摘Drug-induced liver injury(DILI) and herb-induced liver injury is a hot topic for clinicians,academia,drug companies and regulators,as shown by the steadily increasing number of publications in the past 15 years.This review will first provide clues for clinicians to suspect idiosyncratic(unpredictable) DILI and succeed in diagnosis.Causality assessment remains challenging and requires careful medical history as well as awareness of multifaceted aspects,especially for herbs.Drug discontinuation and therapy reconciliation remain the mainstay in patent's management to minimize occurrence of acute liver failure.The second section will address novel agents associated with liver injury in 2014(referred to as 'signals'),especially in terms of clinical,research and drug development implications.Insights will be provided into recent trends by highlighting the contribution of different post-marketing data,especially registries and spontaneous reporting systems.This literature scrutiny suggests:(1) the importance of postmarketing databases as tools of clinical evidence to detect signals of DILI risk;and(2) the need for joining efforts in improving predictivity of pre-clinical assays,continuing post-marketing surveillance and design ad hoc post-authorization safety studies.In this context,ongoing European/United States research consortia and novel pharmaco-epidemiological tools(e.g.,specialist prescription event monitoring) will support innovation in this field.Direct oral anticoagulants and herbal/dietary supplements appear as key research priorities. | Emanuel Raschi Fabrizio De Ponti | 2015 | World Journal of Hepatology2015，7，13： | 6 |
| 4 | Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer显示文摘 | M. Degiuli M. Sasako A. Ponti A. Vendrame M. Tomatis C. Mazza A. Borasi L. Capussotti G. Fronda M. Morino | 2014 | Br J Surg2014，，2： | 5 |
| 5 | Role of three-dimensional imaging integration in atrial fibrillation ablation显示文摘Atrial fibrillation is the most common arrhythmia and in symptomatic patients with a drug-refractory form,catheter ablation aimed at electrically disconnecting the pulmonary veins(PVs) has proved more effective than use of antiarrhythmic drugs in maintaining sinus rhythm during follow-up.On the other hand,this ablation procedure is complex,requires specific training and adequate clinical experience.A main challenge is represented by the need for accurate sequential positioning of the ablation catheter around each veno-atrial junction to deliver point-by-point radiofrequency energy applications in order to achieve complete and persistent electrical disconnection of the PVs.Imaging integration is a new technology that enables guidance during this procedure by showing a three-dimensional,pre-acquired computed tomography or magnetic resonance image and the relative real-time position of the ablation catheter on the screen of the electroanatomic system.Reports in the literature suggest that imaging integration provides accurate visual information with improvement in the procedure parameters and/or clinical outcomes of the procedure. | Roberto De Ponti Raffaella Marazzi Domenico Lumia Giuseppe Picciolo Roberto Biddau Carlo Fugazzola Jorge A Salerno-Uriarte | 2010 | World Journal of Cardiology2010，2，8： | 5 |
| 6 | Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer显示文摘AIM:To assess the clinical diagnostic value of functional imaging,combining quantitative parameters of apparent diffusion coefficient(ADC) and standardized uptake value(SUV)max,before and after chemo-radiation therapy,in prediction of tumor response of patients with rectal cancer,related to tumor regression grade at histology.METHODS:A total of 31 patients with biopsy proven diagnosis of rectal carcinoma were enrolled in our study.All patients underwent a whole body ^(18)FDG positron emission tomography(PET)/computed tomography(CT) scan and a pelvic magnetic resonance(MR)examination including diffusion weighted(DW) imaging for staging(PET1,RM1) and after completion(6.6 wk)of neoadjuvant treatment(PET2,RM2).Subsequently all patients underwent total mesorectal excision and the histological results were compared with imaging findings.The MR scanning,performed on 1.5 T magnet(Philips,Achieva),included T2-weighted multiplanar imaging and in addition DW images with b-value of 0 and 1000 mm^2/s.On PET/CT the SUVmax of the rectal lesion were calculated in PET1 and PET2.The percentage decrease of SUVmax(△SUV) and ADC(△ADC) values from baseline to presurgical scan were assessed and correlated with pathologic response classified as tumor regression grade(Mandard's criteria;TRG1 = complete regression,TRG5 = no regression).RESULTS:After completion of therapy,all the patients were submitted to surgery.According to the Mandard's criteria,22 tumors showed complete(TRG1) or subtotal regression(TRG2) and were classified as responders;9tumors were classified as non responders(TRG3,4 and5).Considering all patients the mean values of SUVmax in PET 1 was higher than the mean value of SUVmax in PET 2(P < 0.001),whereas the mean ADC values was lower in RM1 than RM2(P < 0.001),with a △SUV and △ADC respectively of 60.2%and 66.8%.The best predictors for TRG response were SUV2(threshold of4.4) and ADC2(1.29 × 10^(-3) mm^2/s) with high sensitivity and specificity.Combining in a single analysis both the obtained median value,the positive predictive value,in predicting the different group category response in related to TRG system,presented R^2 of 0.95.CONCLUSION:The functional imaging combining ADC and SUVmax in a single analysis permits to detect changes in cellular tissue structures useful for the assessment of tumour response after the neoadjuvant therapy in rectal cancer,increasing the sensitivity in correct depiction of treatment response than either method alone. | Davide Ippolito Davide Fior Chiara Trattenero Elena De Ponti Silvia Drago Luca Guerra Cammillo Talei Franzesi Sandro Sironi | 2015 | World Journal of Radiology2015，7，12： | 5 |
| 7 | Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology显示文摘The past decade has witnessed an outstanding scientific production focused towards the possible clinical applications of mesenchymal stromal cells(MSCs) in autoimmune and chronic inflammatory diseases. This raised the need of novel standards to adequately address quality, efficacy and safety issues of this advanced therapy. The development of a streamlined regulation is currently hampered by the complexity of analyzing dynamic biological entities rather than chemicals. Although numerous pieces of evidence show efficacy in reducing intestinal inflammation, some inconsistencies between the mechanisms of action of rodent vs human MSCs suggest caution before assigning translational value to preclinical studies. Preliminary evidence from clinical trials showed efficacy of MSCs in the treatment of fistulizing Crohn's disease(CD), and preparations of heterologous MSCs for CD treatment are currently tested in ongoing clinical trials. However, safety issues, especially in longterm treatment, still require solid clinical data. In this regard, standardized guidelines for appropriate dosing and methods of infusion could enhance the likelihood to predict more accurately the number of responders and the duration of remission periods. In addition, elucidating MSC mechanisms of action could lead to novel and more reliable formulations such as those derived from the MSCs themselves(e.g., supernatants). | Giovanni Dothel Emanuel Raschi Roberto Rimondini Fabrizio De Ponti | 2016 | World Journal of Gastroenterology2016，22，41： | 3 |
| 8 | Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms显示文摘 | E. Bugianesi A. Gastaldelli E. Vanni R. Gambino M. Cassader S. Baldi V. Ponti G. Pagano E. Ferrannini M. Rizzetto | 2005 | Diabetologia2005，，4： | 3 |
| 9 | Trans-Septal Catheterization in the Electrophysiology Laboratory显示文摘 | Roberto De Ponti Riccardo Cappato Antonio Curnis Paolo Della Bella Luigi Padeletti Antonio Raviele Massimo Santini Jorge A. Salerno-Uriarte | 2006 | Journal of the American College of Cardiology2006，，5： | 2 |
| 10 | Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages显示文摘Anaemia and thrombocytopenia are haematological disorders that can be detected in many human immunodeficiency virus(HIV)-positive patients during the development of HIV infection. The progressive decline of erythrocytes and platelets plays an important role both in HIV disease progression and in the clinical and therapeutic management of HIV-positive patients. HIV-dependent impairment of the megakaryocyte and erythrocyte lineages is multifactorial and particularly affects survival, proliferation and differentiation of bone marrow(BM) CD34+ haematopoietic progenitor cells, the activity of BM stromal cells and the regulation of cytokine networks. In this review, we analyse the ma-jor HIV-related mechanisms that are involved in the genesis and development of the anaemia and thrombocytopenia observed in HIV positive patients. | Davide Gibellini Alberto Clò Silvia Morini Anna Miserocchi Cristina Ponti Maria Carla Re | 2013 | World Journal of Virology2013，2，2： | 2 |
| 11 | Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial显示文摘 | M Degiuli M Sasako M Calgaro M Garino F Rebecchi M Mineccia D Scaglione D Andreone A Ponti F Calvo | 2004 | European Journal of Surgical Oncology2004，，3： | 2 |
| 12 | Expression andactivity of cyclic and linear analogues of esculentin-1,anantimicrobial peptide from amphibian skin显示文摘 | Ponti D Mignogna G Mangoni M L | 1999 | Eur J Bio-chem1999，263，3： | 1 |
| 13 | Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties显示文摘 | PONTI D COSTA A ZAFFARONI N | 2005 | Cancer Res2005，65，13： | 1 |
| 14 | Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties显示文摘 | Ponti D Costa A Zaffaroni N Pratesi G Petrangolini G Coradini D | 2005 | Cancer Res2005，65，： | 1 |
| 15 | Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia显示文摘 | Ponti RD Uriarte JAS | 2002 | Eur Heart J2002，23，5： | 1 |
| 16 | Role of nitric oxide-and vasoactive intestinal polypeptide-containing neurones in human gastric fundus strip relaxations显示文摘 | TONINI M DE GIORGIO R PONTI F | 2000 | Br J Pharmacol2000，129，1： | 1 |
| 17 | Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties显示文摘 | Ponti D Costa A Zaffaroni N | | 0，，13： | 1 |
| 18 | An innovative approach to the topical treatment of acne 显示文摘 | Sparavigna A Tenconi B De Ponti I | 2015 | Clin Cosmet Investig Dermatol2015，8，： | 1 |
| 19 | Pain control and quality of life after laparoscopic en-block resection of deep infiltrating Endometriosis(DIE)vs incomplete surgical treatment with or without GnRHa administration after surgery显示文摘 | Angioni S Pontis A Dessole M | 2015 | Arch Gynecol Obstet2015，291，2： | 1 |
| 20 | Irritable bowel syndrome:new agents targeting serotonin receptor subtypes显示文摘 | DE PONTI F TONINI M | 2001 | Drugs2001，61，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员